News
Engineered bacteria as an early-stage drug discovery platform against diseases caused by protein misfolding and aggregation
Protein misfolding and aggregation are common pathological features for many human diseases, such as Alzheimer’s disease, type 2 diabetes, amyotrophic lateral sclerosis and cancer. Aiming
Engineering a Thermophilic Microbial Chassis for Synthetic Biology Applications
The OMIC-Engine Athens Hub is working on incorporating the advantages of high-temperature biocatalysis into Synthetic Biology (SB) applications. Led by the Enzyme and Microbial Biotechnology
Refactoring the Conjugation Machinery of Promiscuous Plasmid RP4
Chromosomal exchange and subsequent recombination of the cognate DNA between bacteria was one of the most useful genetic tools (e.g., Hfr strains) for genetic analyses
The long and winding road: accidents and tinkering in software standardization
Software is based on universal principles but not its development. Relating software to hardware is never automatic or easy. Attempts to optimize software production and
Towards the right standards: the intersection of open science, responsible research and innovation, and standards
The introduction of standards in research and development leading to new products or innovative processes can be thought of as a particularly technical approach to
Standardization and social ordering: a change of perspective
In Synthetic Biology, standardization can be viewed as a form of social coordination and ordering. Furthermore, in this social context, standards depend upon social ordering
Which is the standard that you mostly think has to be developed? @kristie_tanner replies: "Maybe an R+D standard. There are standards for very specific things, but nothing especially focused on the management of R+D projects."
Matthew Wook Chang, from the Singapore Consortium for Synthetic Biology, is going to provide us an input from the academia. He insists that we should continue to create an international community that should be accesible to everyone.
It's Markus Schmidt's turn, from @biofaction. Markus is talking about the risk assessment process and safety issues millions of products face throughout the world. Standards could be the solution.